Using tumor analytics to improve cancer treatment with immunotherapy and targeted inhibitors.
Spatiotemporal Tumor Analytics for Guiding Sequential Targeted-Inhibitor: Immunotherapy Combinations (ST-Analytics)
This study is looking at a new way to treat cancer by giving two types of therapies—targeted inhibitors and immunotherapy—in a specific order to see if it works better, especially for people with melanoma and brain metastases. The goal is to find out how to make these treatments more effective and help patients who may not respond well to current options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Institute for Systems Biology NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10916244 on NIH RePORTER |
What this research studies
This research focuses on developing a new approach to cancer treatment by combining targeted inhibitors with immunotherapy in a sequential manner rather than simultaneously. By analyzing past clinical data and using animal models, the researchers aim to understand how this sequence can enhance treatment effectiveness, particularly in melanoma and brain metastases. The study will explore various factors such as dosing, timing, and the order of treatments to optimize patient outcomes. Patients may benefit from more effective treatment strategies that could overcome resistance to current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with melanoma or other cancers that may benefit from sequential immunotherapy and targeted inhibitor treatments.
Not a fit: Patients who do not have melanoma or similar cancers may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that significantly improve patient outcomes.
How similar studies have performed: Previous research has shown promise in using sequential therapies in cancer treatment, suggesting potential for success in this novel approach.
Where this research is happening
Seattle, United States
- Institute for Systems Biology — Seattle, United States (Active)
Researchers
- Principal investigator: Heath, James R. — Institute for Systems Biology
- Study coordinator: Heath, James R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.